论文部分内容阅读
目的 :分析氨溴索联合干扰素以雾化吸入方式为慢性支气管炎病人进行治疗的实际效用。方法 :选择2013年3月至2014年3月接收的64例慢性支气管炎病症急性发作的病人,按照病人进入医院的先后次序把其中32例病人纳入对照组,其他病人则归纳为人数相等的观察组。对照组病人单独接受氨溴索药物治疗,通过雾化吸入方式运用氨溴索以及干扰素为观察组病人实施治疗,统计病人症状缓释情况并进行比较。结果 :观察组总共有29例达到症情完全康复的水平,占比率是90.63%;对照组总共有10例达到症情完全康复的水平,占比率是31.25%,二组慢性支气管炎病情均取得治疗进展,其中观察组病人的康复概率比对照组更高P<0.05。结论 :当患有慢性支气管炎的病人病情突然发作时,运用干扰素以及氨溴索以雾化吸入形式给病人用药能够迅速控制病情,提升治疗的有效性,值得广泛普及。
OBJECTIVE: To analyze the practical utility of ambroxol combined with interferon in the treatment of patients with chronic bronchitis by aerosol inhalation. Methods: Sixty-four patients with acute exacerbation of chronic bronchitis received from March 2013 to March 2014 were enrolled into the control group according to the order of the patients entering the hospital. Other patients were grouped into equal numbers group. Patients in the control group were treated with ambroxol alone, and ambroxol and interferon were used as the observation group to treat the patients through inhalation of aerosolized inhalation, and the sustained-release symptoms were compared and statistically analyzed. Results: A total of 29 patients in the observation group achieved a complete recovery of the disease, accounting for 90.63% of the patients. In the control group, 10 patients achieved complete recovery of the disease, accounting for 31.25% of the patients in the observation group, with chronic bronchitis Treatment progress, the observation group patients rehabilitation probability higher than the control group P <0.05. CONCLUSIONS: When patients with chronic bronchitis have a sudden onset of illness, the use of interferon and ambroxol in the form of aerosolized inhalation can rapidly control the condition and improve the effectiveness of the treatment, which deserves wide spread.